Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) increases with increasing body mass index (BMI). However, approximately 40–50% of obese adults do not develop hepatic steatosis. The level of inflammatory biomarkers is higher in obese subjects with NAFLD compared to BMI-matched subjects without hepatic steatosis. We used a casein injection in high-fat diet (HFD)-fed C57BL/6J mice to induce inflammatory stress. Although mice on a HFD exhibited apparent phenotypes of obesity and hyperlipidemia regardless of exposure to casein injection, only the HFD+Casein mice showed increased hepatic vacuolar degeneration accompanied with elevated inflammatory cytokines in the liver and serum, compared to mice on a normal chow diet. The expression of genes related to hepatic fatty acid synthesis and oxidation were upregulated in the HFD-only mice. The casein injection further increased baseline levels of lipogenic genes and decreased the levels of oxidative genes in HFD-only mice. Inflammatory stress induced both oxidative stress and endoplasmic reticulum stress in HFD-fed mice livers. We conclude that chronic inflammation precedes hepatic steatosis by disrupting the balance between fatty acid synthesis and oxidation in the livers of HFD-fed obese mice. This mechanism may operate in obese individuals with chronic inflammation, thus making them more prone to NAFLD.
Highlights
The prevalence of nonalcoholic fatty liver disease (NAFLD) increases with increasing body mass index (BMI)
TNFα, IL-6 and MCP-1 serum levels were unchanged in the high-fat diet (HFD) group; these cytokine/chemokines were significantly elevated in the serum of HFD+Casein mice compared with control mice (Fig. 1a)
Previous studies have indicated that systemic inflammation is strongly associated with hepatic steatosis and cardiometabolic disorders in obese individuals
Summary
The prevalence of nonalcoholic fatty liver disease (NAFLD) increases with increasing body mass index (BMI). We conclude that chronic inflammation precedes hepatic steatosis by disrupting the balance between fatty acid synthesis and oxidation in the livers of HFD-fed obese mice. This mechanism may operate in obese individuals with chronic inflammation, making them more prone to NAFLD. Compared with LPS, cytokine-only-treated animal models or local inflammation models, the inflammation induced by subcutaneous injection of casein is characterized by increases in the levels of multiple cytokine/chemokines in the serum as well as increased serum amyloid A (SAA, which is like human CRP, a well-known marker for the systemic inflammatory response in patients)[11]. It has been widely used in animal research on atherosclerosis, amyloidosis, chronic kidney disease and liver disease[12,13,14]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.